KYTHERA Biopharmaceuticals, Inc. (KYTHERA) presented additional efficacy data from a third Phase II clinical study with ATX-101, a first-in-class adipolytic agent that is under investigation for the reduction of submental ('under the chin') fat. The expanded analysis focused on additional patient reported outcome measures, including instruments measuring submental fat impact, subject global assessments and subject self-ratings of chin attractiveness...
Pathetic. This forum won't blow up until we can get past our us vs them mentality. Boris was born out of NWP revolution, but didn't achieve it's golden age the Boris community got past it's NWP obsession and created something new and cool. Granted, that golden age lasted about 3 months until ian ruined it,but still. You trolls and creeps need to stop gaging on ian's nuts.